Application of alfentanil combined with remimazolam sedation in laryngeal mask anesthesia

Application of alfentanil combined with remimazolam sedation in laryngeal mask anesthesia: a prospective, single center, double-blind and randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064130

Enrollment

Unknown

Registered

2022-09-27

Start date

2022-09-28

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Remi-Alfen:remimazolam

Alfen-Remi:alfentail

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 65 yeas; 2. ASA grade I-III.

Exclusion criteria

Exclusion criteria: 1. Obesity; 2. Difficult airway; 3. Asthma; 4. Take analgesics; 5. Severe hypertension; 6. Pulmonary heart disease; 7. Pulmonary arterial hypertension; 8. Cardiac insufficiency; 9. Hyperthyroidism; 10. Epilepsy and Psychosis; 11. Allergic to the drugs in the study.

Design outcomes

Primary

Measure	Time frame
Time from induction to LOC, time from anesthesia induction to BIS <= 60;	—

Secondary

Measure	Time frame
vital signs;Characteristics of anesthesia and surgery;	—

Countries

China

Contacts

Public ContactGuan Xuehai

The First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 18587697310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026